Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection
Autore:
Sahu, KM; Sharma, RK; Gupta, A; Gulati, S; Agarwal, DK; Kumar, A; Bhandari, M;
Indirizzi:
Sanjay Gandhi Postgrad Inst Med Sci, Dept Nephrol, Lucknow 226014, Uttar Pradesh, India Sanjay Gandhi Postgrad Inst Med Sci Lucknow Uttar Pradesh India 226014 ia
Titolo Testata:
CLINICAL TRANSPLANTATION
fascicolo: 3, volume: 15, anno: 2001,
pagine: 173 - 175
SICI:
0902-0063(200106)15:3<173:EOLAHC>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRANSPLANTATION;
Keywords:
acute rejection; lipid profile; HMG CoA reductase inhibitor; lovastatin; renal transplant;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
5
Recensione:
Indirizzi per estratti:
Indirizzo: Sharma, RK Sanjay Gandhi Postgrad Inst Med Sci, Dept Nephrol, Raebareli Rd, Lucknow 226014, Uttar Pradesh, India Sanjay Gandhi Postgrad Inst Med Sci Raebareli Rd Lucknow Uttar Pradesh India 226014
Citazione:
K.M. Sahu et al., "Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection", CLIN TRANSP, 15(3), 2001, pp. 173-175

Abstract

3-Hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitors are established anti-lipidemic agents. They also exert immunomodulatory effects. Two recent reports suggest that pravastatin may be useful in decreasing the incidence and severity of acute rejections (ARs) in heart and kidney transplant recipients. We undertook this prospective, randomized, placebo-controlled, double blind trial to investigate the effect of lovastatin on acuterenal allograft rejection. Sixty-five consecutive, one-haplotype-matched, living related first renal transplant recipients were randomized to receiveeither lovastatin 20 mg/d or placebo for 3 months, in addition to cyclosporine, azathioprine, and steroids. Lipid levels, AR episodes, and liver and muscle enzymes were followed for 3 months post-transplant. At the end of the study period, lovastatin had successfully controlled lipid levels. However, there was no effect on AR episodes (15.15% in the treatment group vs. 18.75% in the placebo group).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 12:23:30